Patents by Inventor Robert C. Duncan
Robert C. Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10180431Abstract: Methods and kits for diagnosing and determining prognosis of head and neck squamous cell carcinoma are described.Type: GrantFiled: June 29, 2016Date of Patent: January 15, 2019Assignee: University of MiamiInventors: Elizabeth Franzmann, Lutecia Pereira, Isildinha M. Reis, Robert C. Duncan
-
Patent number: 10180430Abstract: Methods and kits for diagnosing and determining prognosis of head and neck squamous cell carcinoma are described.Type: GrantFiled: April 16, 2015Date of Patent: January 15, 2019Assignee: University of MiamiInventors: Elizabeth Franzmann, Lutecia Pereira, Isildinha M. Reis, Robert C. Duncan
-
Publication number: 20160305942Abstract: Methods and kits for diagnosing and determining prognosis of head and neck squamous cell carcinoma are described.Type: ApplicationFiled: June 29, 2016Publication date: October 20, 2016Inventors: Elizabeth Franzmann, Lutecia Pereira, Isildinha M. Reis, Robert C. Duncan
-
Publication number: 20150219656Abstract: Methods and kits for diagnosing and determining prognosis of head and neck squamous cell carcinoma are described.Type: ApplicationFiled: April 16, 2015Publication date: August 6, 2015Inventors: Elizabeth Franzmann, Lutecia Pereira, Isildinha M. Reis, Robert C. Duncan
-
Publication number: 20140329230Abstract: Methods and kits for diagnosing and determining prognosis of head and neck squamous cell carcinoma are described. An exemplary method for diagnosing head and neck squamous cell carcinoma (HNSCC) in a subject may comprise assaying a saliva sample from the subject for the presence of total protein, solCD44, and HPV, and using the combination of total protein, HPV, and CD44 levels in a multivariate analysis to determine a combined score, whereby an increase in score above a cut-off point distinguishes subjects with HNSCC, or an elevated risk of future occurrence thereof, from subjects without HNSCC or at low risk of future occurrence thereof.Type: ApplicationFiled: November 15, 2012Publication date: November 6, 2014Inventors: Elizabeth Franzmann, Lutecia Pereira, Isildinha M. Reis, Robert C. Duncan
-
Patent number: 8877213Abstract: Targeted disruption of the centrin gene leads to attenuation of growth in the Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.Type: GrantFiled: November 15, 2010Date of Patent: November 4, 2014Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Indian Council of Medical ResearchInventors: Hira L. Nakhasi, Angamuthu Selvapandiyan, Alain Debrabant, Robert C. Duncan, Poonam Salotra, Gannavaram Sreenivas
-
Publication number: 20110081383Abstract: Targeted disruption of the centrin gene leads to attenuation of growth in the Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.Type: ApplicationFiled: November 15, 2010Publication date: April 7, 2011Applicants: The Gov. of the United States as Represented by the Secretary, Dept. of Health and Human Services, Institute of Pathology (ICMR)Inventors: Hira L. Nakhasi, Angamuthu Selvapandiyan, Alain Debrabant, Robert C. Duncan, Poonam Salotra, Gannavaram Sreenivas
-
Patent number: 7887812Abstract: Targeted disruption of the centrin gene leads to attenuation of growth in Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.Type: GrantFiled: February 28, 2006Date of Patent: February 15, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Hira L. Nakhasi, Angamuthu Selvapandiyan, Alain Debrabant, Robert C. Duncan, Poonam Salotra, Gannavaram Sreenivas
-
Publication number: 20070276275Abstract: Estimated heart rate variability (HRV) may be used to determine a heart rate variability index. Based on a relationship between one or more variables and the HRV, a multiple regression analysis may be performed to reduce a confounding effect of the one or more variables on a relationship between the heart rate variability index and the one or more variables. This index may then be normalized from 0-100. A computer, or other suitable device, operatively connected to a field monitor capable of taking an EKG, may determine an HRV index, which can then be used to determine the likelihood of a variety of medical conditions. These conditions can include such things as the likelihood of an abnormality were a computed axial tomography scan to be performed, thus, in some cases, reducing or eliminating the need for performing such a scan.Type: ApplicationFiled: May 23, 2007Publication date: November 29, 2007Applicant: UNIVERSITY OF MIAMIInventors: Kenneth G. Proctor, Robert C. Duncan
-
Patent number: 6928897Abstract: A handlebar extension for a bicycle handlebar includes an armrest portion and an elongate forward portion which is integral with, and extends away from the armrest portion. The handlebar extension is configured such that the armrest portion may be attached to the handlebar of a bicycle with the elongate forward portion extending forwardly away from the handlebar, supported by the armrest portion. A bicycle having a handlebar and a pair of handlebar extensions mounted to the handlebar is also provided.Type: GrantFiled: September 28, 2001Date of Patent: August 16, 2005Inventor: Robert C. Duncan
-
Publication number: 20030150292Abstract: A handlebar extension for a bicycle handlebar includes an armrest portion and an elongate forward portion which is integral with, and extends away from the armrest portion. The handlebar extension is configured such that the armrest portion may be attached to the handlebar of a bicycle with the elongate forward portion extending forwardly away from the handlebar, supported by the armrest portion. A bicycle having a handlebar and a pair of handlebar extensions mounted to the handlebar is also provided.Type: ApplicationFiled: September 28, 2001Publication date: August 14, 2003Inventor: Robert C. Duncan
-
Patent number: 5734016Abstract: The Far Upstream Element (FUSE) of the human c-myc gene stimulates expression in undifferentiated cells. A FUSE binding protein (FBP), also referred to as DROME (DNA-binding regulator of c-myc expression), is active in undifferentiated but not differentiated cell extracts. Cloned FBP exhibits the same DNA-binding specificity as the purified human protein and can trans-activate in a FUSE dependent manner. Sequence-specific binding to the FUSE oligonucleotide requires at least two copies of a repeat-helix unit which defines a new DNA-binding motif. Expression of FBP mRNA declined in parallel with decreased FUSE binding activity upon differentiation suggesting transcriptional regulation of FBP.Type: GrantFiled: October 4, 1996Date of Patent: March 31, 1998Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David L. Levens, Robert C. Duncan, Mark I. Avigan
-
Patent number: 5580760Abstract: The Far Upstream Element (FUSE) of the human c-myc gene, stimulates expression in undifferentiated cells. A FUSE binding protein (FBP), also referred to as DROME (DNA-binding regulator of c-myc expression), is active in undifferentiated but not differentiated cell extracts. Cloned FBP exhibits the same DNA-binding specificity as the purified human protein and can trans-activate in a FUSE dependent manner. Sequence-specific binding to the FUSE oligonucleotide required at least two copies of a repeat-helix unit which defines a new DNA-binding motif. Expression of FBP mRNA declined in parallel with decreased FUSE binding activity upon differentiation suggesting transcriptional regulation of FBP. Features were identified in clones which suggested FBP is also regulated by RNA processing, translation and post-translational mechanisms.Type: GrantFiled: February 22, 1993Date of Patent: December 3, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David L. Levens, Robert C. Duncan, Mark I. Avigan
-
Patent number: 4619813Abstract: A gas absorption system is disclosed. The system comprises a vertical housing having a plurality of superposed absorption stages, each stage comprising a ball bed, a plurality of venturi tubes located below the ball bed through which gas is circulated upwardly from stage to stage, a piping system for circulating an absorption liquid at each stage, the level of the absorption liquid in each stage being maintained by overflow from stage to stage, a nozzle connected to the piping system and centered over each venturi tube pointing upwardly into the ball bed for spraying absorption liquid into the ball bed to react the gas circulated through each stage with the absorption liquid, and a cap for capping each venturi tube to prevent the absorption liquid from dripping from stage to stage through the venturi tubes. Each cap includes gas openings allowing gas to flow upwardly from stage to stage to be reacted with the absorption liquid in the ball bed of each stage.Type: GrantFiled: February 14, 1985Date of Patent: October 28, 1986Assignee: Fraser Inc.Inventors: James A. Healey, Robert C. Duncan, Charles F. Roussel
-
Patent number: 4172650Abstract: A shutterless camera and a film assemblage specifically adapted for use therewith. The film assemblage includes a cassette having an exposure opening and an ingress opening in one wall thereof and an egress opening in another wall. Mounted within the cassette is a focal plane shutter having an exposure aperture therein which is adapted to be driven across a photosensitive area of a film unit to expose the same. The camera includes a motor which is adapted to drive the shutter, i.e., actuate the shutter, thereby exposing a film unit, and film advancing apparatus which is adapted to extend into the ingress opening in the cassette to engage and move the exposed film unit out of the cassette.Type: GrantFiled: November 11, 1977Date of Patent: October 30, 1979Assignee: Polaroid CorporationInventor: Robert C. Duncan
-
Patent number: 3952745Abstract: A disposable diaper is provided with an absorbent pad comprised of airfelt or a similar low-strength absorbent material enclosed by an envelope of wet strength tissue. The absorbent pad is preferably enclosed between a liquid-retaining backsheet and a liquid-pervious topsheet secured in superposed relation to the liquid-retaining backsheet. Because the wet strength tissue envelope surrounding the absorbent core material tends to cling to the wetted pad after removal of the liquid-retaining backsheet, it tends to prevent hydraulic erosion of the absorbent media and therefore interferes with pad flushability. If a non-wet strength tissue is utilized on one or both sides of the absorbent media it will readily dissociate upon immersion in water and thereby promote pad flushability. However, such an absorbent pad lacks integrity in use due to the low strength of the absorbent media employed.Type: GrantFiled: November 19, 1974Date of Patent: April 27, 1976Assignee: The Procter & Gamble CompanyInventor: Robert C. Duncan